Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) Director George Poste sold 11,686 shares of the business’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $20.96, for a total transaction of $244,938.56. Following the completion of the sale, the director now owns 213,907 shares of the company’s stock, valued at $4,483,490.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Exelixis Stock Performance
Shares of EXEL stock traded down $0.02 during mid-day trading on Wednesday, reaching $21.00. The company’s stock had a trading volume of 1,528,552 shares, compared to its average volume of 2,266,373. Exelixis, Inc. has a 1-year low of $18.64 and a 1-year high of $24.34. The company has a market cap of $6.37 billion, a P/E ratio of 32.81, a PEG ratio of 0.57 and a beta of 0.57. The firm’s 50-day moving average is $22.74 and its two-hundred day moving average is $22.30.
Exelixis (NASDAQ:EXEL – Get Free Report) last announced its quarterly earnings data on Tuesday, April 30th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16). Exelixis had a net margin of 11.10% and a return on equity of 8.85%. The business had revenue of $425.23 million during the quarter, compared to analyst estimates of $461.04 million. During the same quarter in the prior year, the company posted $0.12 EPS. The company’s quarterly revenue was up 4.0% compared to the same quarter last year. Sell-side analysts anticipate that Exelixis, Inc. will post 1.16 EPS for the current year.
Institutional Investors Weigh In On Exelixis
Analyst Upgrades and Downgrades
EXEL has been the subject of a number of analyst reports. Stephens initiated coverage on shares of Exelixis in a research note on Tuesday, May 14th. They issued an “equal weight” rating and a $23.00 price objective for the company. Stifel Nicolaus upped their target price on shares of Exelixis from $23.00 to $25.00 and gave the company a “hold” rating in a research note on Friday, February 2nd. William Blair reiterated an “outperform” rating on shares of Exelixis in a research note on Wednesday, May 1st. TD Cowen upped their target price on shares of Exelixis from $25.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Finally, Royal Bank of Canada upped their target price on shares of Exelixis from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Seven analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and a consensus price target of $26.13.
Check Out Our Latest Stock Analysis on EXEL
Exelixis Company Profile
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Recommended Stories
- Five stocks we like better than Exelixis
- Most Volatile Stocks, What Investors Need to Know
- TJX Companies Can Hit New Highs; Double-Digit Upside to Follow
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- A Hidden Gem Retailer With 20% Upside
- How to Invest in Insurance Companies: A Guide
- Zoom Stock’s Earnings Volatility Picked Up a Lot of Buyers
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.